OCUGEN, INC. Revenue
OCUGEN, INC. (OCGN) reported Revenue of $1.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- OCUGEN, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.49M, a 8.38% increase year-over-year.
- OCUGEN, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.53M, a 3.51% increase year-over-year.
- OCUGEN, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was -$193.00K, a 125.26% decline year-over-year.
- OCUGEN, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.75M, a 54.23% increase year-over-year.
- OCUGEN, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $4.41M, a 8.83% increase from fiscal 2024.
- OCUGEN, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $4.05M, a 32.82% decline from fiscal 2023.
- OCUGEN, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $6.04M, a 142.60% increase from fiscal 2022.
- OCUGEN, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $2.49M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.49M 10-Q · filed 2026-08-06 | $3.02M 10-Q · filed 2026-08-06 | $2.83M derived: sum of 3 quarters · filed 2026-08-06 | $4.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.53M 10-Q · filed 2026-05-08 | $1.34M derived: sum of 2 quarters · filed 2026-05-08 | $3.09M derived: sum of 3 quarters · filed 2026-05-08 | $4.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.56M derived: sum of 2 quarters · filed 2026-03-04 | $2.93M derived: sum of 3 quarters · filed 2026-08-06 | $4.41M 10-K · filed 2026-03-04 |
| 2025-09-30 | $1.75M 10-Q · filed 2025-11-05 | $3.13M derived: sum of 2 quarters · filed 2026-08-06 | $4.61M 10-Q · filed 2025-11-05 | $5.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.37M 10-Q · filed 2026-08-06 | $2.85M 10-Q · filed 2026-08-06 | $3.62M derived: sum of 3 quarters · filed 2026-08-06 | $4.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-05-08 | $2.25M derived: sum of 2 quarters · filed 2026-05-08 | $3.38M derived: sum of 3 quarters · filed 2026-05-08 | $4.52M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $764.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.90M derived: sum of 2 quarters · filed 2026-03-04 | $3.04M derived: sum of 3 quarters · filed 2026-03-04 | $4.05M 10-K · filed 2026-03-04 |
| 2024-09-30 | $1.14M 10-Q · filed 2025-11-05 | $2.28M derived: sum of 2 quarters · filed 2025-11-05 | $3.29M 10-Q · filed 2025-11-05 | $4.70M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.14M 10-Q · filed 2025-08-04 | $2.15M 10-Q · filed 2025-08-04 | $3.56M derived: sum of 3 quarters · filed 2025-08-04 | $7.26M derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-03-31 | $1.01M 10-Q · filed 2025-05-09 | $2.42M derived: sum of 2 quarters · filed 2025-05-09 | $6.12M derived: sum of 3 quarters · filed 2025-05-09 | $6.61M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $5.11M derived: sum of 2 quarters · filed 2025-03-05 | $5.59M derived: sum of 3 quarters · filed 2025-03-05 | $6.04M 10-K · filed 2025-03-05 |
| 2023-09-30 | $3.70M 10-Q · filed 2024-11-14 | $4.18M derived: sum of 2 quarters · filed 2024-11-14 | $4.63M 10-Q · filed 2024-11-14 | $5.51M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $485.00K 10-Q · filed 2024-08-08 | $928.00K 10-Q · filed 2024-08-08 | $1.81M derived: sum of 3 quarters · filed 2024-08-08 | $2.27M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $443.00K 10-Q · filed 2024-05-14 | $1.32M derived: sum of 2 quarters · filed 2024-05-14 | $1.79M derived: sum of 3 quarters · filed 2024-05-14 | $2.43M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $879.00K derived: 10-K 12 month − 10-K 9 month · filed 2024-04-16 | $1.34M derived: sum of 2 quarters · filed 2024-04-16 | $1.99M derived: sum of 3 quarters · filed 2024-04-16 | $2.49M 10-K · filed 2024-04-16 |
| 2022-09-30 | $466.00K 10-K · filed 2024-04-16 | $1.11M derived: sum of 2 quarters · filed 2024-04-16 | $1.61M 10-K · filed 2024-04-16 | |
| 2022-06-30 | $643.00K 10-K · filed 2024-04-16 | $1.14M 10-K · filed 2024-04-16 | ||
| 2022-03-31 | $500.00K 10-K · filed 2024-04-16 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 | $0.00 derived: sum of 2 quarters · filed 2019-05-15 | $0.00 derived: sum of 3 quarters · filed 2019-05-15 | $0.00 derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $0.00 derived: sum of 2 quarters · filed 2019-03-22 | $0.00 derived: sum of 3 quarters · filed 2019-03-22 | $0.00 10-K · filed 2019-03-22 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | $0.00 derived: sum of 3 quarters · filed 2019-05-15 | $0.00 derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 | $0.00 derived: sum of 2 quarters · filed 2019-05-15 | $0.00 derived: sum of 3 quarters · filed 2019-05-15 | $0.00 derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $0.00 derived: sum of 2 quarters · filed 2019-03-22 | $0.00 derived: sum of 3 quarters · filed 2019-03-22 | $0.00 10-K · filed 2019-03-22 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |